Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,857,560
  • Shares Outstanding, K 1,293,620
  • Annual Sales, $ 22,127 M
  • Annual Income, $ 5,455 M
  • 36-Month Beta 1.19
  • Price/Sales 3.88
  • Price/Cash Flow 6.85
  • Price/Book 3.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.52
  • Number of Estimates 7
  • High Estimate 1.68
  • Low Estimate 1.32
  • Prior Year 1.37
  • Growth Rate Est. (year over year) +10.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.96 +5.68%
on 02/12/19
70.50 -4.13%
on 02/01/19
-0.93 (-1.36%)
since 01/15/19
3-Month
60.32 +12.05%
on 12/26/18
72.90 -7.28%
on 12/03/18
-2.19 (-3.14%)
since 11/15/18
52-Week
60.32 +12.05%
on 12/26/18
82.71 -18.29%
on 03/13/18
-13.96 (-17.12%)
since 02/15/18

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 1.01% Gain

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $66.74 to a high of $67.06. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

GILD : 67.59 (+1.84%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 112.04 (+1.65%)
FBT : 147.15 (+1.57%)
BBH : 129.21 (+1.20%)
GILD : 67.59 (+1.84%)
AMGN : 188.34 (+0.89%)
BIIB : 332.87 (+2.51%)
ALXN : 129.42 (+2.77%)
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

IBB : 112.04 (+1.65%)
FBT : 147.15 (+1.57%)
BBH : 129.21 (+1.20%)
GILD : 67.59 (+1.84%)
AMGN : 188.34 (+0.89%)
BIIB : 332.87 (+2.51%)
ALXN : 129.42 (+2.77%)
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

MGNX : 21.84 (+3.41%)
LGND : 120.86 (-0.02%)
INCY : 84.15 (+0.88%)
GILD : 67.59 (+1.84%)
SGEN : 71.48 (+4.24%)
REGN : 423.97 (+2.17%)
Coty and Electronic Arts surge while Molson Coors dips

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

ELLI : 98.90 (+0.15%)
UAA : 21.16 (-3.07%)
GILD : 67.59 (+1.84%)
EA : 106.84 (+1.51%)
COTY : 11.04 (-0.36%)
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

VKTX : 9.07 (+0.11%)
MDGL : 135.27 (+0.96%)
GILD : 67.59 (+1.84%)
ICPT : 110.82 (-0.34%)
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational,...

GILD : 67.59 (+1.84%)
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

AVEO : 0.62 (+2.48%)
CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
GILD : 67.59 (+1.84%)
ALKS : 32.54 (+0.12%)
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

AVEO : 0.62 (+2.48%)
CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
GILD : 67.59 (+1.84%)
REGN : 423.97 (+2.17%)
ALKS : 32.54 (+0.12%)
Ralph Lauren surges, Gilead sinks

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

ADM : 41.98 (-0.62%)
ROLL : 142.90 (+5.95%)
GILD : 67.59 (+1.84%)
ENTG : 34.18 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 68.45
1st Resistance Point 68.02
Last Price 67.59
1st Support Level 66.83
2nd Support Level 66.07

See More

52-Week High 82.71
Fibonacci 61.8% 74.16
Fibonacci 50% 71.52
Fibonacci 38.2% 68.87
Last Price 67.59
52-Week Low 60.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar